REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 8, 2024, is entered into by and among ACRIVON THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENT BY AND AMONG ACRIVON THERAPEUTICS, INC., AND THE PURCHASERS AS SET FORTH HEREIN April 8, 2024Securities Purchase Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 8, 2024, by and among Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”).
COMPANY LETTERHEAD]Affiliate Registration Rights Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [__] (collectively, the “Investor”), the parties to this letter hereby agree as follows:
COMPANY LETTERHEAD]Publicity and Board Observer Rights Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [__] and/or one or more of its Affiliates (as defined below) (each, an “Investor” and together, the “Investors”), the parties to this letter hereby agree as follows:
